{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "'...may underlie neurodegeneration' (p. 3)",
          "judgment": "Yes",
          "reasoning": "The paper defines LRRK2 mutations as potentially causing neurodegeneration, establishing a pathogenic disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Used a kinase activity assay to test variant effects on LRRK2 function.",
          "judgment": "Yes",
          "reasoning": "Kinase activity assays are widely used to study LRRK2 function and its role in neurodegeneration.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "sub_step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "'...incubated with wild-type protein...' (p. 4) and '...performed in triplicate...' (p. 5)",
              "judgment": "Yes",
              "reasoning": "The assay used both normal (wild-type) and abnormal (mutant) controls, and experiments were repeated in triplicate.",
              "next_step_or_outcome": "Proceed to Sub-step 3c (Variant Controls)"
            },
            {
              "sub_step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "'...tested variants known to be pathogenic...' (p. 6)",
              "judgment": "Yes",
              "reasoning": "Known pathogenic variants were used as controls in the assay.",
              "next_step_or_outcome": "Proceed to Step 4 (Apply evidence to individual variant interpretation)"
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "sub_step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "'...statistically significant decrease...' (p. 7) and '...p < 0.005...' (p. 8)",
              "judgment": "Yes",
              "reasoning": "The paper reports statistically significant differences between variant and control samples.",
              "next_step_or_outcome": "Proceed to Sub-step 4c (Correlate OddsPath)"
            },
            {
              "sub_step_name": "Sub-step 4c: Correlate OddsPath",
              "extracted_paper_info": "'...OddsPath calculated as 42...' (p. 9)",
              "judgment": "Yes",
              "reasoning": "The paper provides an OddsPath calculation, indicating a strong association between the variant and the observed functional effect.",
              "next_step_or_outcome": "Apply ACMG guidelines for PS3 strength"
            }
          ]
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G2019S variant exhibited a strong decrease in kinase activity compared to wild-type LRRK2, with statistically significant results and a calculated OddsPath of 42, indicating very strong evidence of pathogenicity (PS3_very_strong)."
    }
  ]
}